Shanhai Innovation Secures Nearly RMB 100 Million Series C Funding to Accelerate AI-Driven Supramolecular New Materials R&D and Multi-Industry Commercialization
YuanBio Venture Capital
Venture Capital Institution
VCBeat has learned that a leading domestic enterprise in supramolecular new materialsShenzhen Shinesky Biotechnology Co., Ltd. (hereinafter referred to as “Shinesky Innovation”)Announced today the completion of a nearly RMB 100 million Series C financing round. This round was led byYuanBio Venture CapitalLead Investor.
This financing will inject strong momentum into Shinesky Innovation’s expansion in the field of supramolecular new materials. The funds will be primarily allocated to upgrading and building an AI-driven R&D platform for supramolecular new materials, as well as promoting the industrial application of these materials across multiple sectors, including health-focused food products, pharmaceuticals, agriculture, and environmental protection. Meanwhile, the company will actively expand its new energy business, covering the development of safe electrolytes, recycling of spent batteries, and recovery of silver paste from photovoltaic silicon wafers, thereby facilitating technology accessibility and industrial innovation.
Shenzhen Shinesky Biotechnology Co., Ltd. was founded in 2017 by Professor Zhang Jiaheng, a doctoral supervisor at Harbin Institute of Technology (Shenzhen). It is the world’s first enterprise to systematically apply supramolecular technology to the broader health and industrial sectors. The company’s business scope coversDaily-use cosmetics and their raw materials, biopharmaceuticals, functional foods and their raw materials, medical devices, as well as pesticides and feed additives in the broader health sector; concurrently, it has established a presence in new energy, photovoltaics, and other industries, along with pan-industrial sectors such as precious metal extraction.The company received strategic investments from Bloomage Biotech and L'Oréal in 2022 and 2023, respectively, marking L'Oréal’s first open innovation investment project in China. After four rounds of financing, it has secured investments from renowned institutions including Oriental Fortune Capital, Cowin Capital, Hongtai Fund, Lihe Hongxin, Shenzhen SME Guarantee, Guohua Investment, and Sihai New Materials.
In the project of AI R&D platform for new supramolecular materials, the R&D team of Shinesky Innovation had already attempted to develop functional molecules by leveraging quantum chemistry theories and computational chemistry software tools as early as 2008, and published “Theoretical Study of pKa for perchloric acid” in the Journal of Molecular Structure. In the same year, DeepMind released AlphaFold, a protein structure prediction model that accurately predicts protein structures based on parameters such as intermolecular interactions.
After years of scientific exploration and data accumulation, the Company has initially established the capability to predict supramolecular structures through computational models. On March 18, 2025, Shinesky Innovation announced a strategic collaboration with Deep Principle, an AI for Chemistry/Materials technology company, to jointly create the world’s first AI-powered supramolecular material synthesis matrix—Jianmu™ (SynthrixJIMU). Centered on an intelligent AI engine, this platform integrates chemistry, materials science, and engineering to achieve an end-to-end workflow for supramolecular material design, simulation, and synthesis. It aims to enable demand-driven intelligent creation, precise simulation, efficient validation, and continuous optimization through experiment-linked feedback, significantly accelerating the translation efficiency from laboratory to market.
In the field of cosmetics,Leveraging its core platform technology of supramolecular modification, Shenzhen Shinesky Biotechnology Co., Ltd. has successfully upgraded and developed supramolecular ingredients with efficacies such as whitening and anti-aging, acne treatment and anti-inflammation, soothing and moisturizing, and oil control and cleansing. These innovations address common challenges associated with active ingredients, including poor water solubility, high irritation potential, low stability, and inadequate compatibility, thereby enabling their more effective incorporation into formulations to deliver superior skincare benefits. Currently, Shenzhen Shinesky Biotechnology Co., Ltd. has partnered withL'Oréal, Procter & Gamble, Beiersdorf, Bloomage Biotechnology, Botanee, FuErJia, Freda, Marubihas established partnerships with more than 100 well-known brands.
In the food sector,As the world’s first upstream enterprise to systematically apply supramolecular technology in the pan-health sector, Shinesky Innovation conducts ordered “intelligent” assembly and modification of food ingredients, with applications in food processing, component extraction, quality improvement, and functional enhancement. These technologies are applicable to functional and innovative food products. Key ingredients include a range of functional raw materials such as vitamins, plant extracts, probiotics, and saturated and unsaturated fats.
Shenzhen Shinesky Biotechnology Co., Ltd. has also built up multiple technological reserves in the fields of environmental protection and agriculture.. This includes novel targeted adsorption materials based on supramolecular technology, which can selectively capture micropollutants such as pesticides, pharmaceuticals, and hazardous chemicals from wastewater, as well as carbon materials modified with supramolecular solvents, which can perform oil-water separation in oily wastewater.
YuanBio Venture Capital, the lead investor, is a professional investment firm specializing in the broader healthcare sector, including biopharmaceuticals, medical devices, and healthcare services. With extensive industry resources and a seasoned investment team, YuanBio has achieved remarkable success in fostering the growth of innovative medical enterprises. This investment in Shenzhen Shinesky Biotechnology Co., Ltd. underscores strong recognition from the capital market for the supramolecular new materials sector and the development potential of Shenzhen Shinesky Biotechnology.
Liu Xiao, Managing Director of YuanBio Venture Capitalstated: “China is the world’s second-largest cosmetics consumer market, with a clear demand for localization of domestic raw materials and significant future potential. Leveraging its core technology platform for supramolecular modification, Shenzhen Shinesky Biotechnology Co., Ltd. has pioneered entry into the cosmetics application market, accumulated a robust portfolio of leading clients, and established strong brand recognition among them. Meanwhile, we are also optimistic about Professor Zhang Jiaheng, an atypical scientist-founder, who brings unique commercial vision and strategic planning capabilities. He is poised to lead his team in delivering innovative, high-quality solutions across broader health, agriculture, environmental protection, and other sectors, thereby empowering industry development.””
Professor Zhang Jiaheng, Chairman of Shinesky Innovation“The financing marks a significant milestone in the company’s development. Leveraging the capital and the strategic resources of our investors, we will accelerate the AI-driven R&D and industrialization of supramolecular new materials. Through technological innovation, we aim to provide superior material solutions for the general health food, pharmaceutical, agricultural, and environmental protection sectors, thereby promoting sustainable industry development.” Looking ahead, Shenzhen Shinesky Biotechnology Co., Ltd. will continue to deepen its expertise in the field of supramolecular new materials, drive growth through innovation, deliver higher-value products and services to global consumers, and lead the supramolecular new materials industry to new heights.